A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Advanced Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Jian Zhou)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Locally Advanced Hepatocellular Carcinoma · Metastatic Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v8

Abroad (travel likely)RecruitingPHASE2

Scottsdale, United States · Jacksonville, United States

Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular Carcinoma · Local Advanced Hepatocellular Carcinoma · Alpha-fetoprotein (AFP)-Producing Gastric Cancer

Abroad (travel likely)RecruitingPHASE1

Goodyear, United States · Duarte, United States